Sugi Predict

Sugi Predict / Targets / CYP2A6

CYP2A6

Cytochrome P450 2A6 · P11509 · CYP2A6 on Sugi Atlas →

218,647 patent compounds predicted against CYP2A6, 116,772 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL36453 SCHEMBL36453 1.00 11/20
SCHEMBL38500 SCHEMBL38500 0.54 11/20
SCHEMBL3075 SCHEMBL3075 1.00 8/20
SCHEMBL30032 SCHEMBL30032 0.63 8/20
Naphthalene Naphthalene (SCHEMBL8953) 1.00 7/20
Naphthalene Naphthalene (SCHEMBL49569) 0.89 7/20
Naphthalene Naphthalene (SCHEMBL51882) 0.89 7/20
Naphthalene Naphthalene (SCHEMBL51883) 0.89 7/20
SCHEMBL38501 SCHEMBL38501 0.68 7/20
Anthracene Anthracene (SCHEMBL7703) 0.64 7/20
Benz(B)Anthracene Benz(B)Anthracene (SCHEMBL7947) 0.58 7/20
SCHEMBL25125 SCHEMBL25125 0.58 7/20
SCHEMBL25181 SCHEMBL25181 0.58 7/20
SCHEMBL54728 SCHEMBL54728 0.58 7/20
Phenanthrene Phenanthrene (SCHEMBL7643) 1.00 6/20
SCHEMBL19854 SCHEMBL19854 1.00 6/20
SCHEMBL49861 SCHEMBL49861 1.00 6/20
Naphthalene Naphthalene (SCHEMBL38585) 0.57 6/20
SCHEMBL23664 SCHEMBL23664 0.50 6/20
SCHEMBL26985 SCHEMBL26985 0.39 6/20

Clinical trials — most relevant to CYP2A6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Genetics on Metabolism of Efavirenz PHASE4COMPLETED
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking PHASE4COMPLETED
Pharmacogenetics of Nicotine Addiction Treatment PHASE3COMPLETED
Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients PHASE3COMPLETED
An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder PHASE3COMPLETED
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma PHASE2WITHDRAWN
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL PHASE1/PHASE2UNKNOWN
Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol PHASE1COMPLETED
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot PHASE1COMPLETED
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS) PHASE1COMPLETED
Bioequivalence Trial of a New Opioid Combination Compared to Reference PHASE1COMPLETED
Cotinine Metabolism in Infants and Children PHASE1COMPLETED
Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children PHASE1COMPLETED
A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects PHASE1COMPLETED
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients PHASE1COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults EARLY_PHASE1NOT_YET_RECRUITING
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy nanUNKNOWN
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer nanCOMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics nanCOMPLETED
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk nanCOMPLETED
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis nanCOMPLETED
EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients nanCOMPLETED
CYP2B6 Polymorphisms in Methadone Disposition nanCOMPLETED
Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva nanCOMPLETED
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants nanCOMPLETED
Developing Genetic Education for Smoking Cessation nanCOMPLETED
Laparoscopic vs. Open Distal Gastrectomy After Neoadjuvant Chemotherapy nanNOT_YET_RECRUITING
Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting. nanCOMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CYP2A6 binder may also engage these)

ProteinNameSimilarity
CYP2A13 Cytochrome P450 2A13 1.000 landscape →
CYP2A7 Cytochrome P450 2A7 (EC 1.14.14.1) (CYPIIA7) 0.999 landscape →
P15123 — 0.998 P15123 →
P20812 — 0.998 P20812 →
Q05556 — 0.996 Q05556 →
Q05555 — 0.995 Q05555 →
P20852 — 0.994 P20852 →
CYP2C19 Cytochrome P450 2C19 0.993 landscape →
P15392 — 0.992 P15392 →
P10610 — 0.991 P10610 →
P33264 — 0.991 P33264 →
P33263 — 0.991 P33263 →
P00179 — 0.990 P00179 →
O18809 — 0.990 O18809 →
P00180 — 0.990 P00180 →
Q08078 — 0.990 Q08078 →
O55071 — 0.990 O55071 →
P17666 — 0.989 P17666 →
Q64583 — 0.989 Q64583 →
CYP2C8 Cytochrome P450 2C8 0.989 landscape →
P33272 — 0.989 P33272 →
P00181 — 0.989 P00181 →
P00176 — 0.988 P00176 →
P33265 — 0.987 P33265 →
P24460 — 0.987 P24460 →
CYP2C18 Cytochrome P450 2C18 0.987 landscape →
E9Q5K4 — 0.987 E9Q5K4 →
P56656 — 0.987 P56656 →
Q64458 — 0.987 Q64458 →
P33262 — 0.987 P33262 →